ForPatients
*by Roche*

Alzheimer's Disease (AD)

# A Study of Gantenerumab in Participants With Mild Alzheimer Disease

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Completed | 22 Countries | NCT02051608 2013-003390-95 WN28745 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

Part 1 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab in participants with mild Alzheimer disease. Participants will be randomized to receive either gantenerumab subcutaneously every 4 weeks or placebo subcutaneously every 4 weeks. Approved Alzheimer medication is allowed if on stable dose for 3 months prior to screening. Part 2 is an open-label extension (OLE). A positron emission tomography (PET) imaging substudy will be conducted within the main study. Eligible participants who provide separate informed consent will undergo PET imaging scans using the radioligand florbetapir as a pharmacodynamic measure of changes in brain amyloid load over time.

| Hoffmann-La Roche | Phase 3 |
|---|---|
| Sponsor | Phase |

**NCT02051608 2013-003390-95 WN28745**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | >=50 Years & <= 90 Years | No |